The potential US implementation of a 100% tariff on imported pharmaceuticals could pose a significant disruption for Indian contract development and manufacturing organizations (CDMOs) such as Piramal Pharma, Glenmark, and Sun Pharma. This could lead to market uncertainties for these key players in the pharma industry.

The US tariff threat on certain medicines has caused Indian pharma stocks to decline, with notable drops seen in Biocon, Sun Pharma, Glenmark, Aurobindo, and Ipca Labs by 4-5%. The Nifty Pharma index fell by 3.8% due to these concerns about reshoring production.

Despite the overall bearish trend in April, the pharmaceutical sector stands out, with stocks like Astral, Aurobindo Pharma, Sun Pharma, Glenmark, NALCO, and Oil India performing well. Conversely, ICICI Prudential Life and BEL exhibit negative trends, suggesting potential challenges ahead. Investors should keep a close eye on the critical support at 21,700 for the Nifty index.

Glenmark has entered the weight loss market with Glipiq (semaglutide), priced affordably at ₹1,300-1,800/month. This move aims to increase accessibility and volumes. The company's Q3 revenue rose by 15% YoY, reaching ₹3,901 crore, primarily due to growth in specialty products, global brand expansion, and complex generics, which also boosted the Ebitda margin to 22%.

Glenmark Pharmaceuticals plans to commercialize its first US product, Ryaltris, directly starting April 2026. Currently approved and available in 55 countries, this marks an expansion of the drug's availability into the American market.

Glenmark Pharma has been issued a GST demand for approximately INR 16.1 crores from FY 2019-21. The company, however, expects no significant financial or operational impact and plans to appeal the decision.